Public-registry site landscape for NCT04511130, a Acute Myeloid Leukemia study sponsored by Marker Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04511130 (registry record) |
| Sponsor | Marker Therapeutics, Inc. |
| Condition(s) | Acute Myeloid Leukemia; Stem Cell Transplantation |
| Phase | PHASE2 |
| Listed sites | 18 |
| Site countries | United States |
Eichor generates a preliminary site-risk snapshot for NCT04511130 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →